The funds will be used to evaluate TQL1055, manufactured by Adjuvance, with SARS-CoV2 antigen, manufactured by NIH (National Institutes of Health).
TQL1055 is Adjuvance's novel Saponin vaccine adjuvant. The total funding in this contract is USD 1.47m.
Adjuvance Technologies is a privately held biopharmaceutical company focused on improving health and saving lives through breakthroughs in vaccine adjuvant design.
Its lead adjuvant, TQL1055, is in pre-clinical development for multiple indications in infectious disease, oncology, neurobiology, substance abuse, and allergy.
The National Institutes of Health (NIH), a part of the US Department of Health and Human Services, is the US's medical research agency.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval